Kali Research LLCResearch Access Portal

All compounds are designated Research Use Only (RUO). Not for human consumption, veterinary use, or clinical application.

Research Compound CatalogMetabolic ResearchTirzepatide Research Profile
Metabolic Research
Research Use Only

Synthetic Dual GLP-1/GIP Receptor Agonist Peptide

Tirzepatide

Dual GLP-1/GIP Receptor Agonist Peptide

Research StatusLiterature Reviewed Through: July 2026
Research Use Only
Updated Periodically

Research Profiles are reviewed periodically as new peer-reviewed literature becomes available.

Available Strength
10 mg / vial
CAS Number
2023788-19-2
Metabolic Research laboratory research
Metabolic Research
Research at a Glance

Major published findings — summarized in under 30 seconds.

1
Substantial reductions in body weight have been observed in clinical trials, with results among the most significant reported for compounds in this class.
2
Meaningful improvements in blood sugar control have been documented across multiple large studies.
3
Reductions in cardiovascular risk markers, including blood pressure and lipid levels, have been reported.
4
The compound has been studied in both type 2 diabetes and obesity populations, with consistent findings across groups.
5
Long-term safety data from Phase 3 trials are available in the published literature.

What Is This Compound?

Tirzepatide is a research peptide that activates two biological pathways involved in blood sugar regulation and appetite control. It was developed to combine the effects of two naturally occurring gut hormones — GLP-1 and GIP — into a single compound. Researchers have studied it extensively in the context of type 2 diabetes and obesity, and it has been evaluated in some of the largest metabolic clinical trials conducted to date. Its dual-pathway design is studied to understand whether targeting both receptors together produces different outcomes than targeting either one alone.

Continue below to see what published research has observed so far.

What Has Research Found?

1
Substantial reductions in body weight have been observed in clinical trials, with results among the most significant reported for compounds in this class.
2
Meaningful improvements in blood sugar control have been documented across multiple large studies.
3
Reductions in cardiovascular risk markers, including blood pressure and lipid levels, have been reported.
4
The compound has been studied in both type 2 diabetes and obesity populations, with consistent findings across groups.
5
Long-term safety data from Phase 3 trials are available in the published literature.

Want to understand why these findings occur? Continue to the scientific overview below.

The Science Behind It

Tirzepatide is a synthetic dual agonist peptide that activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). It is structurally based on the native GIP sequence with modifications that confer balanced affinity at both receptors. The compound has been extensively studied in metabolic research contexts, particularly for its effects on glycemic regulation, body weight, and lipid metabolism.

Mechanism of Action

Tirzepatide binds GLP-1R to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via central nervous system pathways. Simultaneous GIPR activation is proposed to enhance the insulinotropic effect in a glucose-dependent manner and may modulate adipocyte function, promoting lipid utilization. The dual mechanism is studied for potential synergistic effects on metabolic parameters that exceed those observed with GLP-1R agonism alone.

Key Research Characteristics
Dual GLP-1R/GIPR agonist with balanced receptor affinity derived from native GIP sequence
Extensively characterized in Phase 3 clinical trials with robust published pharmacology data
Studied for synergistic insulinotropic effects exceeding single GLP-1R agonism
GIP receptor component investigated for adipocyte lipid metabolism modulation
Useful reference compound for comparative incretin receptor pharmacology
Glucose-dependent mechanism of action studied for reduced hypoglycemia risk in research models

Research Applications

Type 2 diabetes and insulin resistance research models
Obesity and body composition studies
Incretin biology and receptor pharmacology
Lipid metabolism and dyslipidemia research
Cardiovascular metabolic risk factor investigation

Compound Specifications

Available Strength
10 mg / vial
Appearance
White to off-white lyophilized powder
Purity
≥98% (HPLC)
Storage Conditions
−20 °C; protect from light and moisture
Storage After Reconstitution
4 °C up to 7 days; −80 °C for long-term storage
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.5 g/mol
CAS Number
2023788-19-2
Research Status
Research Use Only (RUO)

Scientific References

1.Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515.
2.Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. Lancet. 2021;398(10295):143–155.
3.Samms RJ, et al. Functionally Biased GIPR Agonism Mediates Weight Loss in Obese Mice. Cell Metab. 2021;33(8):1727–1741.
4.[Placeholder] Peer-reviewed publication on GIPR adipocyte signaling and lipid metabolism.
5.[Placeholder] Technical reference: receptor binding kinetics and selectivity profile for Tirzepatide.

Placeholder entries are reserved for peer-reviewed publications. All references are provided for scientific context only.

Current State of Research

Research Use Only

All information presented on this Research Profile is intended exclusively for laboratory research purposes. This compound is designated Research Use Only (RUO) and is not intended for human consumption, veterinary use, or any clinical application. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition.

This material is sold solely for in vitro research and laboratory investigation by qualified scientific personnel. Kali Research LLC makes no representations regarding the safety or efficacy of this compound for any use outside of controlled laboratory research settings. Researchers are solely responsible for compliance with all applicable laws and institutional regulations governing the use of research compounds.

Not for human consumptionNot for veterinary useNot for clinical applicationQualified researchers onlyIn vitro / laboratory use
Research Inquiry

Request Information

Need additional technical documentation on Tirzepatide? Submit an inquiry and a member of our team will respond.

Research Profile
Specifications
Available Strength10 mg / vial
AppearanceWhite to off-white lyophilized powder
Purity≥98% (HPLC)
Storage Conditions−20 °C; protect from light and moisture
Storage After Reconstitution4 °C up to 7 days; −80 °C for long-term storage
Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight4813.5 g/mol
CAS Number2023788-19-2

Need additional technical documentation? Submit an inquiry and our team will respond.

Research Use Only (RUO). Not for human consumption, veterinary use, or clinical application.